Compounded tirzepatide is not FDA-approved, so FDA “does not review compounded drugs for safety, effectiveness or quality before they are marketed” [1]. Tirzepatide’s known risks remain relevant, including Zepbound’s warnings, including a boxed warning about thyroid C-cell tumors [3]. Safety here comes down to two layers: the drug’s own risks, and the risks of how it was made and dosed.
Tirzepatide’s known warnings remain relevant
Zepbound’s warnings are important context for a compounded preparation, although its trials do not establish an identical safety profile for that preparation. Its main warnings, in label order [3]:
- Risk of thyroid C-cell tumors (the boxed warning, based on rat studies; human relevance unknown)
- Severe gastrointestinal adverse reactions
- Acute kidney injury due to volume depletion
- Acute gallbladder disease
- Acute pancreatitis
- Hypersensitivity (allergic) reactions
- Hypoglycemia, which is more likely alongside insulin or a sulfonylurea
- Diabetic retinopathy complications in people with type 2 diabetes
- Pulmonary aspiration during general anesthesia or deep sedation
The common side effects are mostly digestive. In the two weight-loss trials, stomach side effects hit 56% of Zepbound users at every dose, compared with 30% of people on placebo [3]. The full stomach picture by dose is on does Zepbound cause constipation, and the full list is on Zepbound side effects.
| Side effect | Placebo | Zepbound 15 mg |
|---|---|---|
| Nausea | 8% | 28% |
| Diarrhea | 8% | 23% |
| Vomiting | 2% | 13% |
| Constipation | 5% | 11% |
| Abdominal pain | 5% | 10% |
| Indigestion (dyspepsia) | 4% | 10% |
Zepbound label, Table 1, Studies 1 and 2 (up to 72 weeks) [3]. These rates come from trials of the approved drug; these trials do not establish the safety of a compounded preparation.
FDA has flagged four problems specific to compounded versions
FDA lists doses beyond the label, fraudulent labels, warm shipments and multi-dose vials kept too long as concerns for compounded GLP-1s [1]. As of May 31, 2026, the agency had received “more than 730 reports of adverse events associated with compounded tirzepatide.” Because state-licensed pharmacies that aren’t outsourcing facilities don’t have to report adverse events, FDA says “it is likely that adverse events from compounded versions of these drugs are underreported” [1].
Fake labels are a real problem, not a theoretical one. FDA says some labels name compounding pharmacies that “do not exist,” and others name a licensed pharmacy that “did not compound these products.” It has one adverse-event report, with redness, swelling, pain and a red lump at the injection site, from a product labeled as compounded tirzepatide by a pharmacy that “did not actually compound the product” [1].
Storage matters too. FDA’s advice is not to use any injectable GLP-1 that shows up warm, and it says multi-dose vials should be used within 28 days of first use [1]. The storage rules are covered in compounded tirzepatide out of the fridge.
Dosing problems are the risk you can most directly guard against
FDA has reports of adverse events possibly linked to compounded tirzepatide prescribed “in doses beyond what is in the FDA-approved drug label.” FDA says this “could mean using more product in a single dose, taking doses more frequently or increasing the amount more quickly” [1]. Some people reported seeking medical care for nausea, vomiting, diarrhea, abdominal pain and constipation.
The practical step is to ask. Ask your prescriber how your dose and schedule compare with the approved label. Have your pharmacist read back the milligram dose printed on what you received. If anything about your dose is unclear, stop and ask before you take it.
What the independent reporting data show
A 2026 study of FDA’s adverse-event database from 2018 to 2024 found that 707 of 81,078 GLP-1 reports involved compounded products [4]. Compared with brand-product reports, compounded reports carried higher odds of hospitalization (reporting odds ratio 2.35), contamination (19.00) and compounding or manufacturing issues (8.51). This observational reporting study cannot establish comparative event rates among all users.
The same study found some surprises. Compounded reports had lower odds of dosing and administration errors than brand reports, and higher odds of suicidality reports (6.34) [4]. Reporting databases can’t show that a drug caused an event, so treat these as signals worth watching, not as risk rates.
B12 add-ins raise a quality question with no answer yet
Scientists at Eli Lilly, which makes Zepbound and Mounjaro, reported a new impurity that forms between tirzepatide and vitamin B12 in mass-compounded products. They wrote that its clinical effects are unknown [5]. The indexed authors list Lilly affiliations; read this as manufacturer-associated laboratory work, not an independent clinical safety trial.
FDA has its own view of add-ins. It has said that a semaglutide-plus-B12 product can still count as “essentially a copy” of the approved drug when the amounts sit within 10% of commercial strengths [2]. The cited evidence does not establish that adding B12 makes tirzepatide safer or more effective.
Quality varies by pharmacy
In a 2026 secret-shopper study of 75 clinics and med spas in two states, 4 of 21 supplier facilities behind compounded GLP-1 sales weren’t licensed for sterile compounding. Three of 22 had faced state discipline [6]. A named, licensed pharmacy is the first thing to look for.
| Risk | Source | Applies to brand too? | What you can do |
|---|---|---|---|
| Stomach side effects | Zepbound label [3] | Yes | Report symptoms that don’t go away |
| Dehydration leading to kidney injury | Label §5.3 [3] | Yes | Drink fluids; report ongoing vomiting or diarrhea |
| Gallbladder disease | Label §5.4 [3] | Yes | Know the symptoms: upper belly pain, fever, yellow skin |
| Pancreatitis | Label §5.5 [3] | Yes | Get care for severe belly pain that won’t stop |
| Thyroid C-cell tumor warning | Boxed warning [3] | Yes | Tell your prescriber about any MTC or MEN 2 history |
| Doses beyond the label | FDA [1] | No | Ask how your dose compares with the label |
| Fraudulent pharmacy labels | FDA [1] | No | Check the pharmacy exists and is licensed |
| Warm delivery | FDA [1] | Storage matters for both | Don’t use a dose that arrives warm |
| Multi-dose vial past 28 days | FDA [1] | No | Discard 28 days after first use |
| Supplier not licensed for sterile compounding | DiStefano 2026 [6] | No | Ask for the pharmacy’s name and license |
| Tirzepatide–B12 impurity | Lilly-authored study [5] | No | Ask whether the product is plain tirzepatide |
Some people shouldn’t take tirzepatide in any form
People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) shouldn’t take it. Neither should anyone with a known serious allergy to tirzepatide or its ingredients [3]. The label also says Zepbound “is not recommended in patients with severe gastroparesis.”
Pregnancy is a stop sign too. The label says tirzepatide may cause fetal harm and should be stopped when pregnancy is recognized [3]. If you take birth control pills, the label advises switching to a non-oral method, or adding a barrier method, for the first 4 weeks of treatment and again for 4 weeks after every dose increase.
How to check a compounded tirzepatide program
- Look up the pharmacy with FDA’s BeSafeRx tool for finding state-licensed online pharmacies [7].
- Ask whether the product is plain tirzepatide, not a salt form or a blend.
- Ask how it ships, and check that it arrives cold.
- Make sure a licensed clinician screens you and stays available after delivery.
- Walk away from any program claiming its product is “the same as” an FDA-approved drug. FDA lists that claim among its telehealth red flags [1].
Scores for programs that prescribe it are on the compounded tirzepatide scores, built on the method set out in how we score. The evidence question is in does compounded tirzepatide work, the legal status is in is compounded tirzepatide still available, and buying options are in where to get compounded tirzepatide. The semaglutide version of this page is is compounded semaglutide safe.
How to report a problem
Report side effects or a suspect product to FDA’s MedWatch program at 1-800-FDA-1088 [3]. Voluntary reports help FDA learn about problems, since many pharmacies are not required to file. A report does not itself establish that the product caused an event.